Jury Still Out On Beta Amyloid Target In Early Alzheimer’s
This article was originally published in The Pink Sheet Daily
Executive Summary
New data analyses at the Alzheimer’s Association International Congress spur some optimism, but analysts advise caution about whether they will actually translate into clinically meaningful benefits in pivotal trials.
You may also be interested in...
Deal Watch: Boehringer’s Busy Week – An Acquisition, A Divestiture And A Discontinuation
Teva’s buyout of Allergan’s generics business should end speculation about a Teva/Mylan merger. A new Sanofi/Regeneron tie-up and an AstraZeneca divestiture to Sanofi’s Genzyme unit are among the latest developments in immuno-oncology.
Biogen Idec Finalizes Phase III Plans For Aducanumab In Alzheimer’s
Though performance of a middle 6 mg/kg dose cohort just disappointed investors in the Phase Ib PRIME trial, company is confident with using this regimen in two large Phase III studies.
Roche Bullish On Alzheimer’s Prospects
Roche has reported a solid performance for the first half of 2015 and provided a promising, though data-light, R&D update. A number of Phase III starts and filing timelines have been confirmed, and the Swiss pharma also gave an update on its Alzheimer's ambitions.